Dare Bioscience Q2 cash $16.4M; Ovaprene Phase 3 enrolling; Sildenafil Cream awaits FDA feedback

Dare Bioscience, Inc.

2024-Q2 EPS reported $0.72 revenue$31,740

Cash and equivalents $16.4M at June 30, 2024; received $22M non-dilutive royalty financing from XOMA in April 2024.
G&A expenses $2.4M, down 17% YoY; R&D expenses $4.9M, down 19% YoY.
Ovaprene Phase 3 contraceptive study recruiting at 20 U.S. sites; ~125 women expected to complete 6 months by Q2 2025.
Sildenafil Cream Phase 3 design pending additional FDA feedback; each Phase 3 study estimated at ~$15M.
Total grants received for DARE-LARC1 now ~$29.3M; pipeline includes DARE-HRT1 in development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.